We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $20B
1-Year Est. Return 154.41%
This Fund
S&P 500
This Quarter Est. Return
+18.97%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$26.5B
AUM Growth
+$1.52B
Cap. Flow
-$117M
Cap. Flow %
-0.44%
Top 10 Hldgs %
84.24%
Holding
133
New
14
Increased
16
Reduced
60
Closed
7

Top Buys

Rank Stock Value
1
ABCL icon
AbCellera Biologics
ABCL
+$478M
2
NVTA
Invitae Corporation
NVTA
+$181M
3
KOD icon
Kodiak Sciences
KOD
+$170M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$52.7M
5
OPT
Opthea Limited American Depositary Shares
OPT
+$41.8M

Top Sells

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$450M
2
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$410M
3
EXAS
Exact Sciences
EXAS
+$188M
4
IMMU
Immunomedics Inc
IMMU
+$20.2M
5
AMRN
Amarin Corp
AMRN
+$19.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.87%
2 Miscellaneous 0.12%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYRE icon
51
Spyre Therapeutics
SYRE
$7.99B
$26.8M 0.1%
136,404
-38,780
-22% -$8.04M
FLGT icon
52
Fulgent Genetics
FLGT
$563M
$25.8M 0.1%
495,573
-50,616
-9% -$2.12M
ADPT icon
53
Adaptive Biotechnologies
ADPT
$3.86B
$22.5M 0.08%
379,682
-60,857
-14% -$3.14M
VSTM icon
54
Verastem
VSTM
$680M
$21.6M 0.08%
+845,337
New +$17M
MREO
55
Mereo BioPharma
MREO
$44.7M
$21.6M 0.08%
+6,030,293
New +$15.1M
ALT icon
56
Altimmune
ALT
$642M
$21.3M 0.08%
1,884,451
-322,504
-15% -$3.8M
AUPH icon
57
Aurinia Pharmaceuticals
AUPH
$2.14B
$19.5M 0.07%
1,410,064
-207,965
-13% -$3.03M
IMTX icon
58
Immatics
IMTX
$1.34B
$19.5M 0.07%
1,805,025
+803,611
+80% +$8.47M
NVAX icon
59
Novavax
NVAX
$1.58B
$18.9M 0.07%
169,706
-17,670
-9% -$1.88M
ACGN
60
DELISTED
Aceragen Inc
ACGN
$16.9M 0.06%
271,376
– –
CBAY
61
DELISTED
Cymabay Therapeutics
CBAY
$16.6M 0.06%
2,893,276
-359,266
-11% -$2.72M
XNCR icon
62
Xencor
XNCR
$1.82B
$16.1M 0.06%
369,370
-40,772
-10% -$1.69M
ALBO
63
DELISTED
Albireo Pharma Inc
ALBO
$15.5M 0.06%
412,466
-136,581
-25% -$4.97M
SGMO
64
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$13.4M 0.05%
857,339
-92,484
-10% -$1.08M
GWPH
65
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$13M 0.05%
112,897
-25,848
-19% -$2.9M
GMDA
66
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$13M 0.05%
1,548,314
+914,990
+144% +$6.19M
KDNY
67
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$11.9M 0.04%
+748,693
New +$11.3M
FPRX
68
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$11.4M 0.04%
+668,000
New +$8.37M
MIRM icon
69
Mirum Pharmaceuticals
MIRM
$6.28B
$11.3M 0.04%
647,313
+94,304
+17% +$1.85M
SPRY icon
70
ARS Pharmaceuticals
SPRY
$448M
$11M 0.04%
+238,095
New +$7.95M
XENE icon
71
Xenon Pharmaceuticals
XENE
$5.64B
$10.6M 0.04%
687,386
-72,922
-10% -$853K
BLUE
72
DELISTED
bluebird bio
BLUE
$9.82M 0.04%
17,523
-1,931
-10% -$1.22M
ISEE
73
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$9.72M 0.04%
1,406,037
– –
ASMB icon
74
Assembly Biosciences
ASMB
$590M
$9.33M 0.04%
128,452
– –
ANAB icon
75
AnaptysBio
ANAB
$1.6B
$9.18M 0.03%
427,179
-60,064
-12% -$1.46M
1 2
3
4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Baker Bros. Advisors's Q4 2020 Portfolio in Review

As of Q4 2020, Baker Bros. Advisors held 133 positions worth $26.5B, up 6.1% from $25B the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Baker Bros. Advisors's Q4 2020 filing shows 14 new, 16 increased, 60 reduced and 7 closed positions. Its largest new stake was AbCellera Biologics: 10,450,180 shares worth $421M. The largest sale was BeOne Medicines Ltd, an estimated $450M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous and Financials.

  • Baker Bros. Advisors's largest Q4 2020 buy was AbCellera Biologics: 10,450,180 shares worth $421M.
  • Baker Bros. Advisors added most to Invitae Corporation in Q4 2020, an estimated $181M increase.
  • Baker Bros. Advisors's biggest Q4 2020 reduction was BeOne Medicines Ltd, cutting an estimated $450M.
  • Baker Bros. Advisors fully exited MyoKardia, Inc. Common Stock in Q4 2020, selling an estimated $410M.
  • Baker Bros. Advisors's ten largest holdings make up 84% of its $26.5B portfolio in Q4 2020.
  • Baker Bros. Advisors opened 14 new positions and closed 7 in Q4 2020.
  • Baker Bros. Advisors's portfolio value rose 6.1% quarter-over-quarter to $26.5B.

Based on Baker Bros. Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.